tirzepatide iih Trial for Idiopathic Intracranial Hypertension | University of Birmingham posted on the topic Compounded GLP-1/GIP (Tirzepatide) - bmiMD

BioFactors 44(2):148157

The severity and duration of nausea vary considerably between individuals and different GLP-1 preparations

Last updated on Nov 11, 2025

Research design and methods Using the data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases, the differences in adverse events across specific subgroups concerning reporter type, sex, age, dose, indication, report year, onset time, and outcome were investigated using the ROR algorithm and Chi-Square Test/Fishers exact test

S., Zhang, L

A weekly injection would require a disutility from administration of less than 0.02 QALYs per year to become preferred over a daily pill